Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis
出版年份 2011 全文链接
标题
Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 5, Pages 2032-2041
出版商
American Society for Microbiology
发表日期
2011-02-08
DOI
10.1128/aac.01550-10
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation
- (2010) C. Plinke et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates
- (2010) J. van Ingen et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Detection by GenoType MTBDRsl Test of Complex Mechanisms of Resistance to Second-Line Drugs and Ethambutol in Multidrug-Resistant Mycobacterium tuberculosis Complex Isolates
- (2010) F. Brossier et al. JOURNAL OF CLINICAL MICROBIOLOGY
- High Level of Cross-Resistance between Kanamycin, Amikacin, and Capreomycin among Mycobacterium tuberculosis Isolates from Georgia and a Close Relation with Mutations in the rrs Gene
- (2009) L. Jugheli et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant Mycobacterium tuberculosis Strains in Multidrug-Resistant Tuberculosis Patients Undergoing Treatment
- (2009) S. Feuerriegel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Allelic Exchange and Mutant Selection Demonstrate that Common Clinical embCAB Gene Mutations Only Modestly Increase Resistance to Ethambutol in Mycobacterium tuberculosis
- (2009) H. Safi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB
- (2009) A. Von Groll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymorphisms Associated with Resistance and Cross-Resistance to Aminoglycosides and Capreomycin in Mycobacterium tuberculosis Isolates from South Korean Patients with Drug-Resistant Tuberculosis
- (2009) L. E. Via et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
- (2009) A. Van Deun et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis
- (2009) M. A. Zaunbrecher et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tuberculosis Drug Resistance Mutation Database
- (2009) Andreas Sandgren et al. PLOS MEDICINE
- Mutations at embB Codon 306 Are an Important Molecular Indicator of Ethambutol Resistance in Mycobacterium tuberculosis
- (2008) A. M. Starks et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Transfer of embB Codon 306 Mutations into Clinical Mycobacterium tuberculosis Strains Alters Susceptibility to Ethambutol, Isoniazid, and Rifampin
- (2008) H. Safi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates
- (2008) H. J. Marttila et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates
- (2008) Zhaogang Sun et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- emb nucleotide polymorphisms and the role of embB306 mutations in Mycobacterium tuberculosis resistance to ethambutol
- (2008) Shashikant Srivastava et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started